1. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA
2. Howard Hughes Medical Institute, Cold Spring Harbor, New York 11724, USA
3. Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York 10021, USA
4. These authors contributed equally to this work.

Correspondence to: Scott W. Lowe^1,2 Correspondence and requests for materials should be addressed to S.W.L. (Email: lowe@cshl.edu).

Abstract

Although cancer arises from a combination of mutations in oncogenes and tumour suppressor genes, the extent to which tumour suppressor gene loss is required for maintaining established tumours is poorly understood. p53 is an important tumour suppressor that acts to restrict proliferation in response to DNA damage or deregulation of mitogenic oncogenes, by leading to the induction of various cell cycle checkpoints, apoptosis or cellular senescence^{1, 2}. Consequently, p53 mutations increase cell proliferation and survival, and in some settings promote genomic instability and resistance to certain chemotherapies³. To determine the consequences of reactivating the p53 pathway in tumours, we used RNA interference (RNAi) to conditionally regulate endogenous p53 expression in a mosaic mouse model of liver carcinoma^{4, 5}. We show that even brief reactivation of endogenous p53 in p53-deficient tumours can produce complete tumour regressions. The primary response to p53 was not apoptosis, but instead involved the induction of a cellular senescence program that was associated with differentiation and the upregulation of inflammatory cytokines. This program, although producing only cell cycle arrest in vitro, also triggered an innate immune response that targeted the tumour cells in vivo, thereby contributing to tumour clearance. Our study indicates that p53 loss can be required for the maintenance of aggressive carcinomas, and illustrates how the cellular senescence program can act together with the innate immune system to potently limit tumour growth.

1. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA
2. Howard Hughes Medical Institute, Cold Spring Harbor, New York 11724, USA
3. Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York 10021, USA
4. These authors contributed equally to this work.

Correspondence to: Scott W. Lowe^1,2 Correspondence and requests for materials should be addressed to S.W.L. (Email: lowe@cshl.edu).

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.